The BRCA-1 tumour supressor gene was identi®ed on the basis of mutations which occur in familial breast cancer indicating that its inactivation can cause this disease. Although BRCA-1 does not appear to be mutated in sporadic breast cancer, its expression has been shown to be reduced in tumour material from such cases. We show here that mammary tumours which have reduced levels of BRCA-1 expression show enhanced expression of the Brn-3b POU family transcription factor at both the mRNA and protein levels. This elevated expression of Brn-3b is not found in normal mammary cells, benign tumours or in malignant tumour samples which do not exhibit reduced levels of BRCA-1. In contrast, no correlation was noted between BRCA-1 and expression of the related factor Brn-3a. Moreover, Brn-3b but not Brn-3a can strongly repress the BRCA-1 promoter approximately 20-fold in mammary tumour cells. To our knowledge, this is the ®rst report of a transcription factor which regulates BRCA-1 expression. Thus, Brn-3b may play an important role in regulating expression of BRCA-1 in mammary tumours with enhanced expression of Brn-3b resulting in reduced BRCA-1 expression and thereby being potentially important in tumour development.
Introduction
The POU (Pit-Oct-Unc) family of transcription factors was originally de®ned on the basis of a common 150 ± 160 amino acid domain which was found in the mammalian transcription factors Pit-1, Oct-1 and Oct-2, and the nematode regulatory protein Unc-86 (for review see Verrijzer and van der Vliet, 1993; Ryan and Rosenfeld, 1997) . The common POU domain constitutes the DNA binding domain of these proteins and consists of two portions, a POU-speci®c domain which is unique to the POU factors and a POUhomeodomain which is related to the homeobox found in a number of other transcription factors.
Following the identi®cation of the original POU family transcription factors, a number of other members of this family have been de®ned (see Verrijzer and van der Vliet, 1993; Ryan and Rosenfeld, 1997; He et al., 1989) and shown to play critical roles in the regulation of gene expression. Moreover, mutations in the genes encoding several of these factors have been shown to be responsible for particular human diseases. Thus, for example, mutation in the gene encoding Pit-1 has been shown to result in a failure of pituitary gland development and consequent dwar®sm in both mice and humans (for review see Anderson and Rosenfeld, 1994 ) whilst a mutation in the gene encoding Brn-4 has been shown to result in X-linked deafness (de Kok et al., 1995) . More recently, the gene encoding the POU factor Brn3c has been shown to be mutated in a family with progressive late onset deafness (Vahaua et al., 1998) .
Brn-3a, Brn-3b and Brn-3c are closely related members of the POU family which are encoded by dierent genes (Theil et al., 1993) and are expressed in distinct but overlapping patterns in the developing and adult nervous system (He et al., 1989; Gerrero et al., 1993; Lillycrop et al., 1992; Turner et al., 1994; Ninkina et al., 1993) . In addition however, expression of Brn-3a and Brn-3b has also been detected in some non neuronal cells such as cervical epithelium (Lillycrop et al., 1992; Ndisang et al., 1998) and in the testis (Budhram-Mahadeo et al., submitted) .
Interestingly Brn-3a has been shown to be over expressed in aggressive neuro endocrine tumours (Leblond-Francillard et al., 1997) , whilst both Brn-3a and Brn-3b are expressed at high levels in human neuroblastomas (Smith and Latchman, 1996; Latchman, 1997) . Moreover, we have recently shown that mean Brn-3a levels are increased over 300-fold in human samples exhibiting cervical intra-epithelial neoplasia grade 3 (CIN3) compared to normal human cervical samples whereas Brn-3b levels are similar in the two groups of samples (Ndisang et al., 1998) . Such a ®nding is of particular interest in view of the ability of Brn-3a to activate the human papilloma virus type 16 and type 18 promoter whereas Brn-3b represses this promoter (Morris et al., 1994) . In view of the altered expression of Brn-3a and Brn-3b in a variety of dierent tumour cells and our previous detection of these factors in the human breast cancer cell line MCF-7 (Budhram-Mahadeo et al., 1997) we have therefore investigated the expression of Brn-3 and Brn-3b in normal human mammary tissue and in mammary tumours.
Results
To quantitate the level of Brn-3a and Brn-3b mRNAs we used a reverse transcriptase/polymerase chain reaction (RT ± PCR) assay which we have previously used to reliably quantitate these mRNAs in small amounts of clinical and other material (Ndisang et al., 1998; Smith and Latchman, 1996) . This assay was used to compare the levels of Brn-3a and Brn-3b mRNAs in normal breast tissue or benign breast tumour material with that obtained from malignant breast tumours from pre-or post-menopausal women. The mean levels of Brn-3a and Brn-3b (Figures 1 and 2 ) both showed some increase in the material prepared from the premenopausal malignant tumours compared to that obtained from normal/benign tumour material and a further increase was observed in both cases in the postmenopausal tumour material but this was not statistically signi®cant (P40.05 in all comparisons of normal versus tumour levels).
Interestingly however, clear dierences were noticed in the distribution pattern of Brn-3a and Brn-3b expression levels in the dierent tumour samples. Thus, Brn-3a levels appeared to show a continuous distribution between the dierent samples. In contrast, Brn-3b levels exhibited a bipartite distribution in the dierent tumour samples with approximately 40% of the samples showing low levels of Brn-3b within the range observed for the normal samples whilst the remaining samples showed much higher levels outside the normal range. This bipartite distribution was observed for tumour samples obtained from both pre-and post-menopausal women (Figure 2b ).
To determine whether this bipartite distribution had any functional signi®cance, we searched for dierences between the tumour samples with respectively low or high levels of Brn-3b expression. In particular, we examined the level in the dierent samples of the mRNA encoding BRCA-1 protein which is mutated in many cases of familial breast cancer Futreal et al., 1994) and which has also been reported to exhibit reduced expression in non-hereditary (sporadic) breast cancer (Thompson et al., 1995) . Most interestingly, the levels of BRCA-1 in the dierent samples showed an inverse expression pattern to that observed with Brn-3b ( Figures 3 and 4) . Thus, the samples with low levels of Brn-3b exhibited high levels of BRCA-1 which was observed in the samples Figure 1 followed by densitometric scanning, in normal/benign mammary material or in malignant mammary tumours from pre-menopausal or post-menopausal women derived from both pre-menopausal (Figure 4a ; r=0.50 in regression analysis) and post-menopausal ( Figure  4b ; r=0.12) women, although the eect was particularly marked in the samples from pre-menopausal women. A similar correlation was also noted in dierent samples of normal mammary material or material from benign tumours (Figure 4c ; r=0.48). As expected, BRCA-1 levels were greatly reduced in some of the tumour samples compared to the normal samples ( Figure 4 ) in accordance with the data of Thompson et al. (1995) .
In contrast to the results with Brn-3b, the level of BRCA-1 mRNA in malignant material from premenopausal or post-menopausal women or from normal/benign material showed no correlation with the level of Brn-3a mRNA in the dierent samples (Figures 5 and 6 ; in regression analysis, r=0.0004 for pre-menopausal malignant material, r=0.05 for postmenopausal malignant material, r=0.08 for normal samples). The speci®c association of high Brn-3b levels with low BRCA-1 expression was con®rmed by dividing the samples into those with high Brn-3b and low Brn-3b. BRCA-1 levels were highly elevated in the sample group with low Brn-3b compared to the level in those with high Brn-3b. This eect was statistically signi®cant (P50.001 comparing BRCA-1 levels in the high and low Brn-3b expressing groups).
To con®rm these results at the protein level, we carried out Western blotting experiments using speci®c antibodies to measure the levels of Brn-3b and BRCA-1 proteins in malignant breast cancer tissue. As illustrated in Figure 7 , the same inverse correlation between Brn-3b and BRCA-1 was observed at the protein level with the samples having high levels of Brn-3b showing reduced levels of BRCA-1 and viceversa. Moreover, when samples were divided into those with high or low Brn-3b, BRCA-1 protein levels were signi®cantly reduced in the group with low Brn-3b (P50.001). These ®ndings therefore raise the possibility that the Brn-3b transcription factor may have an inhibitory eect on expression of BRCA-1, with the high levels of Brn-3b mRNA and protein observed in some malignant mammary tumour samples being associated with a low level of BRCA-1 mRNA and protein. To investigate this possibility further, we co-transfected MCF7 cells with expression vectors encoding Brn-3a or Brn-3b and a construct in which a four kilo-base fragment of the BRCA-1 promoter drives expression of a luciferase reporter gene.
In this experiment ( Figure 8 ) the activity of the promoter was reduced by approximately 50% in the sample co-transfected with Brn-3a compared to the level observed in the sample co-transfected with the corresponding expression vector lacking any insert. However, a much more dramatic inhibitory eect was observed in the sample co-transfected with the Brn-3b expression vector where promoter activity was reduced to approximately 5% of that observed in the sample transfected with empty expression vector. This eect was speci®c for Brn-3b since co-transfection of a p53 expression vector with the BRCA-1 promoter had no eect on promoter activity. Brn-3a, Brn-3b and p53 expression vectors all drove similar levels of protein in the transfected cells (data not shown) in accordance with our previous results (Budhram-Mahadeo et al., 1995; Morris et al., 1994) . Similar results were also obtained with a reporter construct containing only 400 base pairs of the BRCA-1 promoter indicating that this eect was dependent on this short promoter region (data not shown). This eect was speci®c to the BRCA-1 promoter, since transfection of the same Brn-3b expression vector with reporters containing an oestrogen response element resulted in a strong stimulatory eect on the promoter in accordance with our previous results (BudhramMahadeo et al., 1997) (data not shown). Hence Brn-3b can indeed directly inhibit the BRCA-1 promoter in cotransfections into breast cancer cells.
Discussion
BRCA-1 was originally de®ned as a gene whose germ line mutation confers a marked susceptibility to breast and ovarian cancer Futreal et al., 1994) with approximately 45% of families with hereditary breast cancer and more than 80% of families with inherited breast and ovarian cancer showing mutation of this gene (for review see Casey, 1997) . Subsequent studies suggested that the protein product of the BRCA-1 gene may play a key role in inhibiting the proliferation of mammary cells so that its inactivation by mutation leads to an enhanced risk of tumour formation. Thus, overexpression of BRCA-1 results in a growth inhibition in vitro of all breast and ovarian cancer cell lines tested as well as inhibiting the in vivo growth of tumour cells implanted in nude mice (Holt et al., 1996) . Similarly, anti-sense RNA directed against BRCA-1 and hence reducing its expression level, results in the transformation of mouse ®broblasts (Rao et al., 1996) and stimulates the proliferation of mammary epithelial cells (Thompson et al., 1995) .
Although these results provide an explanation for the key role of BRCA-1 in speci®c cases of inherited susceptibility to breast cancer where the corresponding gene is mutated, they do not indicate whether it has a similar role in the more common sporadic form of breast cancer. To date there is no evidence for BRCA-1 mutations in late onset, sporadic breast cancer . Interestingly however, one study has shown that the expression of BRCA-1 mRNA in normal human mammary epithelial tissue is between ®ve-and 15-fold higher than in samples derived from invasive breast cancer (Thompson et al., 1995) . Moreover, the majority of these sporadic tumour samples do not exhibit allele-speci®c dierences in expression from the two copies of the BRCA-1 gene suggesting that the reduced expression is not due to a regulatory mutation in one copy of the gene (Thompson et al., 1995) .
It is likely therefore that in these sporadic breast cancer cases, the altered BRCA-1 expression level is caused by changes in the activity of speci®c cellular transcription factors which regulate expression of BRCA-1. The data presented here indicate that the POU family transcription factor Brn-3b may well regulate BRCA-1 expression in this manner. Thus, the reduced levels of BRCA-1 mRNA and protein which we observe in a number of samples derived from malignant breast cancer tissue, are associated with elevated levels of Brn-3b expression compared to those observed in normal mammary tissue or in other mammary tumours not exhibiting reduced levels of BRCA-1 expression. Moreover, arti®cial over expression of Brn-3b has a very strong inhibitory eect on the BRCA-1 promoter reducing its activity approximately 20-fold whereas Brn-3a has only a weak inhibitory eect.
Brn-3b has previously been reported to have a stimulatory eect on promoters containing an oestrogen response element in mammary cancer cells (Budhram-Mahadeo et al., 1997) . Hence, it appears that Brn-3b can have a stimulatory or an inhibitory eect in mammary cells depending upon the promoter involved. Such a dual role for Brn-3b has previously been reported in neuronal cells where its eects have been better characterized. Thus, Brn-3b can activate the promoters of the neuronal nicotinic acetyl choline receptor a2 gene (Milton et al., 1995) and the synapsin 1 gene whereas it represses the activity of a number of other neuronal promoters such as those derived from the genes encoding SNAP-25 (Morris et al., 1997) ainternexin (Budhram-Mahadeo et al., 1995) and the neuro®laments (Smith et al., 1997) and also inhibits Figure 8 Luciferase reporter assay of MCF7 cells co-transfected with a promoter/reporter construct containing the full length BRCA-1 promoter together with expression vector lacking any insert (V) or the same vector expressing either Brn-3a, Brn-3b or p53. Values have been equalized relative to the activity obtained in the co-transfection with the reporter construct and empty expression vector (set at 100%) and are the mean of ®ve determinations whose standard deviation is shown by the bars their activation by the closely related Brn-3a factor Budhram-Mahadeo et al., 1995; Smith et al., 1997) . In contrast, Brn-3b has no eect on the promoter of the Bcl-2 proto-oncogene, although this promoter is also activated by Brn-3a (Smith et al., 1998) .
Further detailed studies of the BRCA-1 promoter will be necessary to determine the exact target sequences and mechanisms by which Brn-3b represses this promoter. It is already clear however, that Brn-3b is able to repress BRCA-1 expression in mammary tumour cells and that its over expression in such cells is associated with reduced expression of BRCA-1. To our knowledge, Brn-3b is the ®rst transcription factor which has been reported to regulate BRCA-1 expression. It will be of particular interest in the future therefore, to examine the expression levels of Brn-3b during normal mammary gland development to determine whether its expression shows an inverse pattern to that of BRCA-1 (Lane et al., 1995; Marquis et al., 1995) . Similarly, the potential role of Brn-3a and Brn-3b in the regulation of oestrogen receptormediated gene expression (Budhram-Mahadeo et al., 1997) indicates that one or both of these factors may play a role in the increase in BRCA-1 expression which occurs in mammary cells following oestrogen treatment (Lane et al., 1995; Marquis et al., 1995; Gudas et al., 1995) .
Material and methods

Normal and breast cancer samples
Total RNA from normal mammary gland and from malignant breast tumours (from pre and post menopausal women) was obtained from the Candis Tissue Bank Research Centre Liverpool University. Samples for protein analysis were obtained from Dr D Barnes, Guys Hospital London.
Reverse transcriptase/polymerase chain reaction assay About 0.1 mg of RNA from each sample was used as a template for cDNA synthesis. The synthesized cDNA was used in RT ± PCR assays as previously described (Morris et al., 1994) using the following oligonucleotide primers: Brn-3a: 5'-GTCGACATGGACTCGGACACG-3', 3'-ACGGTGAA-TGACTCCCCCGA-5'; Brn-3b: 5'-GGAGAAGAAGCGC-AAGC-3', 3'-CTGAGAACCGGAGAGGTCT-5'. Amplification of the invariantly expressed human cyclophilin mRNA used as a control was carried out in parallel using the following primers: 5'-TTGGGCCGCGGTACTCCTTTCA-3', and 3'-TTTCGTATGGCCCAGGACCG-5'. BRCA-1 primers were S-GCACATTTATTACAGGACCACA3' and 5'-ACTTCCACCTCAGCCT ATTTTT (Bennett et al., 1995) .
In all cases, 20 ml of each PCR product was fractionated on a 2% agarose gel and blotted onto Hybond-N+ nylon membrane (Amersham International, Little Chalfont, UK) and hybridized with homologous complimentary 32 P-labelled probes. Membranes were exposed to ®lms, (Eastman Kodak Co., Rochester, NY, USA) and the subsequent autoradiographs were then analysed using a densitometer (Bio-Rad Laboratories, Hercules, CA, USA). We have previously shown that this blotting procedure, in conjunction with the RT ± PCR conditions used, allows accurate quanti®cation of the Brn-3a and Brn-3b mRNAs relative to the constitutively expressed cyclophilin mRNA (Lillycrop et al., 1992; Ndisang et al., 1998; Morris et al., 1994) .
Western blotting
Breast tissue samples were resuspended in sample buer containing 2.3% sodium dodecyl sulphate, 0.0625 M Tris/ HCl, pH 7.9, 10% glycerol, 5% b-mercaptoethanol and bromophenol blue. Samples were sonicated for 10 s, and then boiled for 2 min. The samples had equal protein content as determined by the method of Bradford (Bradford, 1976) and were split in two and 10 mg of protein run on each of two sides of the same SDS-polyacrylamide gel. After electrophoresis, one half of the gel was stained with Coomassie blue and then destained, while the other half was transferred to nitrocellulouse and probed with antibody to BRCA-1 (Ab1:-Oncogene Science) or Brn-3b (Bab Co Ltd) as previously described (Dhillon et al., 1993) . Levels of BRCA-1 or Brn-3b in each sample were quantitated by densitometric scanning of the resulting autoradiograph. Dierences in the level of total protein in each sample were determined by scanning the actin band on the stained portion of the gel to normalize the samples .
Plasmid constructs
The Brn-3a and Brn-3b expression vectors contain full length cDNA clones under the control of the moloney murine leukaemia virus promoter and have previously been described (Theil et al., 1993; Morris et al., 1994) . The BRCA-1 promoter/reporter constructs contain 4 kilo-bases or 400 bases of upstream sequence containing the BRCA-1 a and b promoters cloned into the pGL2 luciferase vector.
Transient transfection
MCF7 cells were routinely grown in Dulbecco's modi®ed Eagle's medium containing L-glutamate and phenol red which was supplemented with 10% foetal calf serum and 10 ng of insulin per ml. Before experiments were carried out subcon¯uent cells were maintained in phenol red-free Dulbecco's modi®ed Eagle's medium containing 10% dextran coated charcoal-striped foetal calf serum prepared according to the method described by Migliaccio et al. (1993) and 10 ng of insulin per ml for 72 h. The medium was replaced by 5 ml of fresh medium 12 h prior to transfection.
Transfection of plasmid DNA was carried out according to the method of Gorman (Gorman, 1985) . Routinely 5 mg of reporter DNA and 5 mg of each expression vector were transfected into 5610 5 cells and the cells harvested after 72 h. The amount of DNA taken up by the cells in each case was measured by slot blotting of 15 ml of the extract and hybridization with a probe derived from the ampicillin resistance gene in the plasmid vector (Abken, 1992) . Dierences in the intensity of the bands were measured by densitometry and used to equalize the volumes of extracts used for subsequent assay. All transfections also included an internal reporter gene encoding the renilla luciferase with a dual luciferase assay being carried out to control for transfection eciency. Luciferase assays were done as described by the manufacturers (Promega) protocol with results measured on a Turner 20-E luminometer.
